Mechanism-Based Inactivation of Cytochrome P450s 1A2 and 3A4 by Dihydralazine in Human Liver Microsomes

Dihydralazine is known to induce immunoallergic hepatitis. Since anti-liver microsome (antiLM) autoantibodies found in the serum of the patients react with P450 IA2, it is suggested that dihydralazine is biotransformed into a reactive metabolite, which covalently binds to cytochrome P450 IA2 and triggers an immunological response as a neoantigen. We investigated inactivation of P450 enzymes, including P450 IA2, during the metabolism of dihydralazine to evaluate the selectivity of P450 IA2 as a catalyst and a target of dihydralazine. Human liver microsomes or microsomes from lymphoblastoid cells expressing P450 enzymes were preincubated with dihydralazine in the presence of NADPH, followed by an assay of several monooxygenase activities. Preincubation of human liver microsomes with dihydralazine in the presence of NADPH resulted in decreases in phenacetin O-deethylase activity (an indicator of P450 IA2 activity) and testosterone 6be1ta-hydroxylase activity (P450 3A4), but not in diclofenac 4ʹ-hydroxylase activity (P450 2C9), an indication of inactivation of P450s IA2 and 3A4 during the dihydralazine metabolism. The inactivation of both of the P450s followed pseudo-firstorder kinetics and was saturable with increasing dihydralazine concentrations. Similar timedependent decreases in the activities were obtained in the case for use in microsomes expressing P450 IA2 and P450 3A4 instead of the human liver microsomes. The data presented here demonstrated that dihydralazine was metabolically activated not only by P450 IA2 but also by P450 3A4, and the chemically reactive metabolite bound to and inactivated the enzyme themselves, suggesting that dihydralazine is a mechanism-based inactivator of P450s IA2 and 3A4. The data support the postulated covalent binding of a reactive metabolite of dihydralazine to P450 IA2 as a step in the formation of anti-LM antibodies in dihydralazine hepatitis, but it is not the unique factor for determining the specificity of the autoantibodies.